Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
26.27
-0.53 (-1.98%)
At close: Apr 28, 2026, 4:00 PM EDT
26.39
+0.12 (0.44%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Company Description
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States.
The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Paul A. Wagner |
Contact Details
Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States | |
| Phone | 310 618 6994 |
| Website | fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419041 |
| CUSIP Number | 34962G109 |
| ISIN Number | US34962G2084 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician and Director |
| Christopher Roenfeldt | Chief Operating Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2026 | 424B5 | Filing |
| Apr 9, 2026 | 8-K | Current Report |
| Apr 8, 2026 | 424B5 | Filing |
| Apr 1, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 10-K | Annual Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 29, 2026 | SCHEDULE 13G/A | Filing |
| Jan 20, 2026 | SCHEDULE 13G | Filing |
| Jan 9, 2026 | SCHEDULE 13G/A | Filing |
| Dec 23, 2025 | SCHEDULE 13G | Filing |